BXNDA — BLS Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- AU$211.42m
- AU$209.18m
- AU$29.29m
Brief: Bioxyne Ltd Says Receipt Of Certificate Of GMP Compliance With Europe, Others
Brief: Bioxyne Says FY25 Revenue Guidance Upgraded To A$28M
Australia's Bioxyne surges after raising fiscal year revenue outlook
Brief: Bioxyne Posts A$7.2 Mln Q3 Revenue
Brief: Bioxyne Signs Exclusive A$7M Manufacturing And Supply Agreement With NectarTek Australia
Brief: Bioxyne To Raise A$3 Mln At A$0.025 Per Share
Brief: Bioxyne Seeks Trading Halt
Brief: Bioxyne Posts A$8.1 Mln Q2 Revenue
Brief: Bioxyne Posts Quarterly Revenue Of A$4.6 Million
Brief: Bioxyne Posts Revenue Of A$3.1 Million For Quarter
Australia's Bioxyne rises on deal for manufacturing psilocybin products
Brief: Bioxyne And CY Biopharma Forge Strategic Alliance To Develop New Psilocybin Therapies In Austrasia
Brief: Bioxyne Says Received Firm Commitments To Raise A$1.45 Million At A$0.01 Per Share
Brief: Bioxyne Posts HY Loss Attributable A$12.3 Million
Brief: Bioxyne Says Awarded Gmp Manufacturing License For Medical Cannabis
Australia's Bioxyne jumps on unit securing manufacturing license for medical cannabis
Brief: Bioxyne Qtrly Group Revenue About A$2.1 MLN, Up 75%
Brief: Bioxyne Updates On Australian Medicinal Cannabis Business
Brief: Bioxyne Signs Joint Venture With Canxchange